Posted by Michael Wonder on 12 May 2020
Investigators propose different measures for biosimilar equivalence
12 May 2020 - Investigators use the HERITAGE trial findings to argue for a more precise way of measuring clinical equivalence for biosimilars.
Choosing appropriate clinical end points and analysis procedures is essential to both establish clinical equivalence of biosimilars and convince physicians and patients that the agents are worthy of use.
In a recent study, investigators use the HERITAGE study to argue for a more accurate system for measuring biosimilar equivalence.
